Ramucirumab Takes Steps Forward in Gastric Cancer

Abstract Eli Lilly's ramucirumab, a VEGF receptor 2 inhibitor, may offer a much-needed second-line treatment option for patients with advanced gastric or gastroesophageal junction cancer, according to results from the REGARD phase III clinical trial.